Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Government-Owned Inventions; Availability for Licensing

AGENCY: Office of Technology Transfer, Centers for Disease Control and

Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

The inventions named in this notice are owned by agencies of the

United

[[Page 28046]]

States Government and are available for licensing in the United States

(U.S.) in accordance with 35 U.S.C. 207 to achieve expeditious

commercialization of results of federally funded research and

development. Foreign patent applications are filed on selected

inventions to extend market coverage for U.S. companies and may also be

available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent

applications listed below may be obtained by writing to Marjorie

Hunter, Licensing Specialist at the Technology Transfer Office, Centers

for Disease Control and Prevention (CDC), Mailstop E-67, 1600 Clifton

Rd., Atlanta, GA 30333, telephone (404) 639-6271; facsimile (404) 639-

6266. A signed Confidential Disclosure Agreement will be required to

receive copies of the patent applications.

Methods and Compositions for an Artificial Lung Organ Culture System

Quinn, F. D.; Birkness, K. A.

Filed 23 September 94

Serial No. 08/679,081 (Ref # E-14)

Methods have been developed creating an artificial lung culture

system, comprised of multiple human cell layers, for studying the

passage of pathogens and chemical substances through the organ. The

system is comprised of an endothelial cell layer and an alveolar

epithelial cell layer oriented on either side of, and in direct contact

with, an artificial microporous membrane. This stable culture system

provides a more complex system for study than simple monolayers of

human cells or animal models. The culture system is easily maintained

without the use of antibiotics and is viable for longer periods of time

than other models. (Portfolio: Human Organ, Tissue Culture, Liver.)

Infectious cDNA Clones for Dengue Virus: Strain 16881 and Live

Attenuated Vaccine Derivative, Strain PDK-53

Kinney, R. M.; Gubler, D. J.; Trent, D. W.; Halstead, S. B.; Chang, J.;

Butrapet, S.; Bhamarapravati, N.

Filed 7 June 95

Serial No. 08/483,292 (Ref # E-132-95/0)

A quadravalent vaccine which evokes immunity against all four

serotypes of dengue virus comprising DEN-2 PDK-53 infectious clone

derivative, DEN-2/1, DEN-2/3, or DEN-2/4 viruses, and related methods

of immunization are described in this invention. The invention also

provides a method of cloning and sequencing a cDNA copy of an entire

RNA genome of the PDK-53 vaccine derivative of dengue 2 virus, strain

16681, which can be used to engineer new dengue vaccines as well as

recombinant chimeric viruses. This invention provides a host cell with

multiple constructs of protein encoded by several nucleotide sequences.

(Portfolio: Vector-borne Infectious Diseases, Vaccine, Dengue, Chimeric

Viruses.)

SecA Gene of Mycobacterium Tuberculosis and Related Methods and

Compositions

Quinn, F. D.; Owens, M. H.; King, C. H.

Filed 22 February 95

Serial No. 08/394,646 (Ref # E-066-95/0)

This invention includes an isolated nucleic acid encoding a SecA

protein of Mycobacteria tuberculosis. This nucleic acid can be a native

coding sequence for the SecA protein or any alternative coding sequence

for the SecA protein of M. Tuberculosis. An isolated fragment of the

secA gene that is specific for M. Tuberculosis is also provided. A

purified SecA protein of M. Tuberculosis which comprises the sequence

set forth in the Sequence Listing as SEQ ID NO: 2 is provided.

Fragments of the M. Tuberculosis SecA protein, a purified mutant SecA

protein of M. Tuberculosis, and a purified mutant M. Tuberculosis

expressing the mutant SecA protein are provided in the invention.

The invention provides methods of screening for putative M.

Tuberculosis virulence factors translocated by the SecA protein. In one

example of the method (the method comprises: inhibiting the

translocation ATPase activity of the M. Tuberculosis SecA protein, and

detecting the accumulation of precursor forms of proteins in the

cytoplasm of the M. Tuberculosis cells) the accumulation of a precursor

indicating the presence of a translocation ATPase activity of the M.

Tuberculosis SecA protein can be inhibited by administering an amount

of sodium azide to M. Tuberculosis cells or by mutating the secA gene

so that it produces a non-lethal translocation ATPase deficient M.

Tuberculosis mutant.

Treating HIV Infection by Inhibiting Bcl-2

Sandstrom, P. A.; Folks, T. M.

Filed 29 January 96

Serial No. 08/593,407 (Ref # E-102-

95/0)

This invention provides a method of treating an HIV infection by

inhibiting Bcl-2 expression or activity. This invention also provides a

method of screening for a compound that inhibits HIV replication. This

invention also provides a cell line transfected with a nucleic acid

that encodes Bcl-2, wherein the cell line expresses bcl-2, and the cell

line is infected with HIV. (Portfolio: HIV, AIDS, Viral Infection,

Cellular Biology.)

Methods for Sensitive Detection of Reverse Transcriptase Activity

Heneine, W.; Folks, T. M.; Switzer, W. M.; Yamamoto, S.

Filed 27 January 95

Serial No. 08/379,851 (Ref # E-232-

93/0)

This invention provides a method for detecting a retrovirus in a

biological sample by identifying the presence of the enzyme reverse

transcriptase (RT). This RT assay employs a PCR-based amplification

system to detect a known cDNA product of the RT reaction. This

invention is highly sensitive and specific and requires no knowledge of

viral genomic sequence. Retroviruses that previously would have gone

undetected may now be identified. (Portfolio: PCR, Reverse

Transcriptase, Retrovirus, Diagnosis.)

Nucleotide Sequences of New Hantavirus--``Bayou Virus''

Nichol, S.; Morzunov, S.; Ksiazek, T.; Rollin, P.; Spiropoulou, C.

Filed 17 February 95

Serial No. 08/390,888 (Ref # E-183

-93/2)

Nucleotide sequences of the M and S segments of the Louisiana virus

genome have been identified. Included are several different methods of

detecting the ``Bayou'' hantavirus and isolated nucleic acids specific

for the ``Bayou'' hantavirus. Purified antigenic polypeptides and

antibodies that specifically bind to the ``Bayou'' hantavirus or those

polypeptides are provided. (Portfolio: Hantavirus, Bayou.)

Nucleic Acids of a Novel Hantavirus and Reagents for Detection and

Prevention of Infection. The ``Sin Nombre'' Hantavirus

Rollin, P.; Elliott, L.; Ksiazek, T.; Nichol, S.

Filed 24 June 94

Serial No. 08/569,242 (Ref # E-183-

93/3)

This invention describes a nucleotide sequence for a new

hantavirus, referred to as ``Sin Nombre'' hantavirus, which is the

causative agent of hantavirus pulmonary syndrome. A method of detection

of the ``Sin Nombre'' hantavirus and an associated method of prevention

of infection is provided. The

[[Page 28047]]

``Sin Nombre'' virus strain was previously known as the ``Muerto

Canyon'' hantavirus. (Portfolio: Hantavirus, Diagnosis.)

The Black Creek Canal Strain of Hantavirus and Methods of Detection and

Prevention of Infection Therefrom

Nichol, S. T.; Elliott, L.; Ksiazek, T. G.; Morzunov, S.; Ravkov, E.;

Rollin, P. E.

Filed 17 February 95

Serial No. 08/390,361 (Ref # E-183-

93/4)

The Black Creek Canal strain of hantavirus, which is responsible

for a case of hantavirus Pulmonary Syndrome in Florida, is provided.

The virus was isolated from a rodent and is genetically different at

the nucleotide level from the Muerto Canyon virus. The invention also

provides purified polypeptides encoded by the nucleic acids, purified

antibodies that bind the hantavirus, and describes methods of detection

and prevention. (Portfolio: Hantavirus, Vaccine, Black Creek Canal

Strain.)

Method and Composition for Diagnosing Cat Scratch Disease and Bacillary

Angiomatosis Caused by Rochalimaea Henselae (Now Referred to as

Bartonella Henselae)

Regnery, R. L.; Anderson, B.E.

Patent Issued: 21 March 95

Patent No. 5,399,485 (Ref # E-048-92/0)

This invention provides a method of diagnosing cat scratch disease

and bacillary angiomatosis by detecting the presence of Bartonella

henselae or an immunogenically specific determinant thereof in humans

or animals. Also provided is a vaccine comprising an immunogenic amount

of a nonpathogenic Bartonella henselae and a pharmaceutically

acceptable carrier. (Portfolio: Vaccine, Cat Scratch Disease,

Bartonella.)

Method for Detection of a New Marker Associated With Hepatitis Delta

Virus Infection

Fields, H. A.; Khudyakov, Y.; Favorov, M.

Patent Issued: 29 August 95

Patent No. 5,445,932 (Ref # E-069-92/0)

Reagents and methods for the detection of a marker which is

associated with severe forms of hepatitis delta have been developed.

This invention detects the presence of anti-HDAg' antibodies in a

biological sample. It also describes a vaccine comprised of

immunogenically active HDAg' polypeptides in a pharmaceutically

acceptable carrier. (Portfolio: Hepatitis Delta, Vaccine, Diagnosis.)

DNA Sequence Encoding a Cynomolgus Monkey Hepatitis A Virus Capsid

Protein

Nainan, O. V.; Margolis, H. S.; Robertson, B. H.; Brinton, M. A.;

Ebert, J. W.

Patent Issued: 4 July 95

Patent No. 5,430,135 (Ref # E-089-91/1)

This invention relates to substantially pure preparations of the

cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55,

which may be used in the prevention of hepatitis A in animals. This

invention provides a virus that may be adapted in a cell-line suitable

for human vaccine development or may be cloned into an expression

vector in which the cDNA coding for the capsid region of the virus may

provide a virus-like antigen which could substitute for the whole

virus. (Portfolio: Hepatitis A, Diagnosis, Vaccine.)

Nucleic Acid Probes and Methods for Detecting Candida DNA Cells in

Blood

Lot, T. J.; Morrison, C. J.; Reiss, E.; Lasker, B.; Zakroff, S.

Patent Issued: 20 June 95

Patent No. 5,426,027 (Ref # E-118-93/0)

An isolated double-stranded nucleic acid sequence specific for

Candida albicans, as well as ITS2 sequences for C. Parapsilosis, C.

Tropoicalis, C. Glabrata and C. Krusei, is provided. This invention

also contemplates an isolated nucleic acid that specifically hybridizes

with, or selectively amplifies, a nucleic acid of C. albicans. These

sequences may be used in a rapid method of diagnosing systemic

candidiasis in patients by detecting C. albicans in blood samples with

concentration as low as 10 cells per ml. (Portfolio: Nucleic Acid

Sequencing, Candida, Diagnostics.)

Ear Based Hearing Protector/Communication System

Franks, J. R.; Sizemore, C. W.; Dunn,

D. E.

Patent Issued: 20 June 95

Patent No. 5,426,719 (Ref # E-154-91/0)

A combination hearing protector and communication device which may

be incorporated into earmuffs/earplugs has been developed. The system

allows dual channels and does not compromise the noise-reducing

characteristics of normal earmuffs or earplugs. The system incorporates

an independent transmission channel with the wearer having the

possibility of receiving the same channel as other wearers. (Portfolio:

Ear Protection, Communication, Hearing Safety.)

PsaA

Russell, H.; Sampson, J.; O'Connor, S.

Patent Issued: 6 June 95

Patent No. 5,422,427 (Ref # E-157-91/0)

The patent claims a DNA sequence encoding a pneumonacoccal surface

adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial

protein. This sequence may be utilized to relates to produce a PsaA

polypeptide. The sequence may also be utilized to design diagnostics

for measuring the amount of PsaA contained in a sample. Vaccines which

may be efficacious in adults or children may be developed using the

sequence or polypetides. (Portfolio: Vaccine, Diagnosis, Pneumococal

Surface Adhesin A Protein.)

Streptococcus Pneumoniae 37-KDa Surface Adhesin A Protein

Sampson, J.; Russell, H.; Tharpe, J.; Ades, E.; Carlone, G.

Filed 17 September 1996

Serial No.08/715,131 (Ref # E-157-91/4)

This invention provides the isolated nucleic acid encoding the 37-

kDa protein of Streptococcus pneumoniae designated pneumococcal surface

adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial

protein. This invention relates to purified polypetides encoded by the

sequence and a method of measuring the amount of PsaA contained in a

sample. This invention also includes a vaccine that may be efficacious

in adults or children. (Portfolio: Vaccine, Diagnosis, Pneumococal

Surface Adhesin A Protein.)

Use of Human Immortalized Endothelial Cells to Isolate and Propagate

Ehrlichia chaffeensis and Ehrlichia canis

Dawson, J. E.

Patent Issued: 28 March 95

Patent No. 5,401,656 (Ref # E-155-91/0)

This invention provides a purified immortalized human endothelial

cell infected with Ehrlichia Chaffeensis or Ehrlichia canis. The

invention provides a method for simultaneously screening a human

subject for E. Chaffeensis or Rickettsia rickettsii. Also provided is a

method of culturing E. chaffeensis and E. Canis. (Portfolio: Diagnosis,

Ehrlichiosis, Cell Culture.)

Immunoreactive HTLV-I/II and POL Peptides

Lal, R. B.

Patent Issued 3 January 1995

Patent No. 5,378,805 (Ref # E-172-90/0)

This invention relates to a peptide having specific

immunoreactivity to antibodies to HTLV-I, HTLV-II derived from the

structural gene products from groups consisting of Env-1, Env-2,

[[Page 28048]]

Env-5, Gag-1a, and Pol-3. This invention is further directed to an

immunoassay method for the detection of antibodies, a peptide

composition containing these peptides, and a vaccine. (Portfolio: HTLV,

Vaccine, Diagnostics.)

Methods and Compositions for Diagnosing HTLV-1 Associated Myelopathy

and Adult T-Cell Leukemia

Rudolph, D. L.; Lal, R. B.

Patent Issued 30 May 1995

Patent No. 5,420,244 (Ref # E-206-93/0)

This invention provides antigenic peptides derived from

immunodominant epitopes of the HTLV-I tax or rex proteins that are

immunoreactive with antibodies associated with disease in HTLV-I

infected subjects. This invention provides peptides corresponding to

the immunodominant epitopes of the rex regulatory protein of HTLV-I.

This invention provides methods for diagnosing HTLV-I associated

myelopathy. This invention also provides methods for diagnosing adult

T-cell leukemia. (Portfolio: HTLV-I, HIV, Antibodies, HAM [HTLV-I

Associated Myelopathy], T-cell Leukemia, Diagnosis.)

Isolation of Diagnostic Glycoproteins to Taenia Solium, Immunoblot-

assay and Method for the Detection of Human Cysticercosis

Tsang, V. C. W.; Brand, J.; Boyer, A.; Wilson, M.; Schantz, P.;

Maddison, S.

Patent Issued 11 October 94

Patent No. 5,354,660 (Ref # E-185-88/1)

This invention is a method and a kit for diagnosing active human

neurocysticercosis utilizing an immunoblot assay. This method allows

diagnosis of neurocysticercosis by the detection antigens of larval

origin. This invention improves on the specificity and sensitivity of

the disc method achieving 98% sensitivity and 100% specificity. This

allows the detection of antibodies in the serum or cerebrospinal fluid.

(Portfolio: Larval Detection, Taenia solium, Neurocysticercosis,

Diagnosis.)

Exchangeable Template Reaction

Khudyakov, Y.; Fields, H.

Patent Issued: 2 April 96

Patent No. 5,503,995 (Ref # E-184-91/1)

This invention provides a method of making synthetic DNA of any

desired sequence. This invention can be used to make an array of DNA

having specific substitution in a known sequence which are expressed

and screened for improved function. This invention provides a method

for the synthesis of DNA based on a cyclic mechanism of combining

deoxyoligonucleotides. Also included is a kit comprising a series of

unique synthesized single-stranded deoxypolynucleotides which can be

enzymatically treated to form a unique 3' single-stranded protrusion

for selective cyclic hybridization with another unique single-stranded

deoxypolynucleotide of the series.(Portfolio: DNA, DNA Synthesis.)

Sequences of the Hemagglutinins of Recent Strains of Influenza Type B

virus

Rota, P. A.; Hemphill, M. L.

Patent Issued: 20 December 94

Patent No. 5,374,717 (Ref # E-224-92/0)

This invention provides sequence analyses for recent strains of

Influenza Type B virus. This invention also provides a method for

vaccinating a mammal against influenza type B. This invention also

provides a method of detection and diagnosis of an infection with

influenza type B virus. (Portfolio: Virus, Influenza Type B, Vaccine.)

Method for Detecting Isocyanates

Streicher, R. P.

Patent Issued 11 October 94

Patent No. 5,354,689 (Ref # E-215-92/0)

This invention provides a method for detecting the presence of

isocyanate in a sample. Also, the invention provides a method of

quantifying the total isocyanate presence by quantifying the reaction

product. This invention is particularly well-suited to the detection of

isocyanates in air. (Portfolio: Isocyanate, Detection.)

Portable Spirometer With Improved Accuracy

Hankinson, J. L.; Viola, J. C.; Ebeling, T. H.

Patent Issued 8 October 96

Patent No. 5,562,101 (Ref # E-030-92/1)

This invention is a spirometric measurement device with an

arrangement for computation of a dynamic correction factor to

compensate for temperature-related changes. This invention improves the

accuracy by increasing the analog-to-digital conversion resolution, by

modifying the dithering process, and by compensating for the inherent

transducer temperature drift. This invention provides for a multi-

functional, downloadable, flexible spirometric device, that requires no

disassembly with improved quality control. (Portfolio: Spirometric,

Lung Capacity, Respiratory Function.)

Dated: May 16, 1997.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for

Disease Control and Prevention (CDC).

[FR Doc. 97-13427 Filed 5-21-97; 8:45 am]

BILLING CODE 4163-18-P